Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/07/23
End: 06/30/27
Due: 06/30/28
Phase: N/A
Priority: Normal
Start: 12/16/24
End: 08/15/28
Due: 08/15/29
Phase: N/A
Priority: Normal
Start: 04/01/23
End: 10/30/24
Due: 10/30/25
Phase: N/A
Priority: Normal
Start: 10/30/23
End: 02/12/25
Due: 02/12/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Rescue of Nephrons With ALE.F02 (RENAL-F02) | NCT06047171 | Alentis Therapeutics AG | user2@example.com | None | 2023-09-07 | 2027-06-30 | 2028-06-30 | - | - | 2025-07-14 |
| A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | NCT06747585 | Alentis Therapeutics AG | user2@example.com | None | 2024-12-16 | 2028-08-15 | 2029-08-15 | - | - | 2025-07-14 |
| A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis | NCT05939947 | Alentis Therapeutics AG | user2@example.com | None | 2023-04-01 | 2024-10-30 | 2025-10-30 | - | - | 2025-07-14 |
| Study of ALE.C04 in Patients With Head and Neck Cancer | NCT06054477 | Alentis Therapeutics AG | user2@example.com | None | 2023-10-30 | 2025-02-12 | 2026-02-12 | - | - | 2025-07-14 |